NCT01579916已完成4 期
A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 303
- 试验地点
- 4
- 主要终点
- Percentage of Participants Reporting Fever Within 7 Days Post Vaccination
研究概览
简要总结
This prospective annual release study was designed to assess the safety of a trivalent influenza virus vaccine using two new strains recommended for the 2012-2013 influenza season not previously contained in the trivalent intranasal FluMist vaccine.
Three hundred healthy adults will receive a single dose of vaccine or placebo and will be followed for 180 days after study vaccination.
详细描述
This prospective, randomized, double-blind, placebo-controlled release study will enroll approximately 300 healthy adults 18 to 49 years of age. Eligible subjects will be randomly assigned in a 4:1 fashion to receive a single dose of trivalent vaccine or placebo by intranasal spray. Randomization will be stratified by site.
This study will be conducted at 3 sites in the United States of America. Each subject will receive one dose of investigational product on Study Day 1. The duration of study participation for each subject is the time from study vaccination through 180 days after study vaccination.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 49 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age 18 through 49 years at the time of investigational product administration
- •Written informed consent and any locally required authorization (ie, HIPAA in the USA) obtained from the subject/legal representative prior to performing any protocol-related procedures, including screening evaluations
- •Females of childbearing potential who are sexually active with a nonsterilized male partner must use effective contraception for 30 days prior to study vaccination, and must agree to continue using such precautions for 60 days after study vaccination
- •Nonsterilized males who are sexually active with a female partner of child-bearing potential must use an effective method of contraception from prior to study vaccination amd must agree to continue using such precautions for at least 30 days after receipt study vaccination
- •Healthy by medical history and physical examination
- •Female subjects of child-bearing potential must also have a negative urine or blood pregnancy test at screening and, if screening and Day 1 do not occur on the same day, on the day of vaccination prior to randomization.
- •Subject available by telephone
- •Ability to understand and comply with the requirements of the protocol, as judged by the investigator
- •Ability to complete follow-up period of 180 days after dosing as required by the protocol
排除标准
- •Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results
- •Concurrent enrollment in another clinical study up to 180 days after receipt of investigational product (Day 181)
- •Employees of the clinical study site or any other individuals involved with the conduct of the study, or immediate family members of such individuals
- •History of hypersensitivity to any component of the vaccine, including egg or egg protein or serious, life threatening, or severe reactions to previous influenza vaccinations
- •History of hypersensitivity to gentamicin
- •Any condition for which the inactivated influenza vaccine is indicated, including chronic disorders of the pulmonary or cardiovascular systems (eg, asthma), chronic metabolic diseases (eg, diabetes mellitus), renal dysfunction, or hemoglobinopathies that required regular medical follow-up or hospitalization during the preceding year
- •Acute febrile (> 100.0°F oral or equivalent) and/or clinically significant respiratory illness (eg, cough or sore throat) within 14 days prior to randomization
- •Any known immunosuppressive condition or immune deficiency disease, including human immunodeficiency virus infection, or ongoing immunosuppressive therapy
- •History of Guillain-Barré syndrome
- •A household contact who is severely immunocompromised (eg, hematopoietic stem cell transplant recipient, during those periods in which the immunocompromised individual requires care in a protective environment); additionally, subject should avoid close contact with severely immunocompromised individuals for at least 21 days after study vaccination
- •Receipt of any investigational agent within 30 days prior to randomization, or expected receipt through 30 days after study vaccination (use of licensed agents for indications not listed in the package insert is permitted)
- •Receipt of any non-study vaccine within 30 days prior to randomization, or expected receipt through 30 days after study vaccination
- •Expected receipt of antipyretic or analgesic medication on a daily or every other day basis from randomization through 14 days after study vaccination
- •Administration of intranasal medications within 14 days prior to randomization, or expected receipt through 14 days after study vaccination
- •Receipt of influenza antiviral therapy or antiviral agents within 48 hours prior to study vaccination or expected receipt of influenza antiviral therapy or antiviral agents through 14 days after study vaccination
- •Known or suspected mitochondrial encephalomyopathy
- •Nursing mother
结局指标
主要结局
Percentage of Participants Reporting Fever Within 7 Days Post Vaccination
时间窗: Study Days 1 - 8
A comparison of the rate of fever, defined as oral temperature greater than or equal to 101 degrees Fahrenheit, reported during the 7 days post administration of investigational product between the trivalent influenza virus vaccine and placebo groups.
次要结局
- Percentage of Participants Reporting Other Solicited Symptoms Within 7 Days Post Vaccination(Study Days 1- 8)
- Percentage of Participants Reporting Any Adverse Event (AE) Within 7 Days Post Vaccination(Study Days 1 - 8)
- Percentage of Participants Reporting Other Solicited Symptoms Within 14 Days Post Vaccination(Study Days 1 - 15)
- Percentage of Participants Reporting Any Adverse Event (AE) Within 14 Days Post Vaccination(Study Days 1 - 15)
- Percentage of Participants Reporting Any Serious Adverse Event (SAE) Within 28 Days Post Vaccination(Study Days 1 - 29)
- Percentage of Participants Reporting Any Serious Adverse Event (SAE) Within 180 Days Post Vaccination(Study Days 1 - 181)
- Percentage of Participants Reporting Any New Onset Chronic Diseases (NOCDs) Within 28 Days Post Vaccination(Study Days 1 - 29)
- Percentage of Participants Reporting Any New Onset Chronic Diseases (NOCDs) Within 180 Days Post Vaccination(Study Days 1 - 181)
- Percentage of Participants Who Used Antipyretic or Analgesic Agents Within 7 Days Post Vaccination(Study Days 1 - 8)
- Percentage of Participants Who Used Antipyretic or Analgesic Agents Within 14 Days Post Vaccination(Study Days 1 - 15)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
4 期
A Prospective Study to Evaluate the Safety of a New Trivalent Intranasal Influenza VaccineInfluenzaNCT00677820MedImmune LLC300
已完成
4 期
A Prospective Study to Evaluate the Safety of a New Monovalent Intranasal Influenza VaccineHealthyNCT00873912MedImmune LLC300
已完成
4 期
Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in AdultsHealthyInfluenzaNCT01859143MedImmune LLC300
已完成
4 期
Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 SeasonInfluenzaHealthyNCT03158038MedImmune LLC300
已完成
4 期
Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 SeasonHealthyInfluenzaNCT02743117MedImmune LLC301